Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 878 Results

Title
Intervention Indication Therapeutic Area Year Actions
Baloxavir marboxil for the treatment of influenza in patients aged 12 years and older and are at high risk of developing influenza complications Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2020 View  |  Download
Baloxavir marboxil for the post-exposure prevention of influenza in people aged 12 years and older Baloxavir marboxil (Xofluza; S-033188) Influenza Infectious Disease 2020 View  |  Download
Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) – second line Brexucabtagene autoleucel (Tecartus; KTE-X19) Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2017 View  |  Download
Axicabtagene ciloleucel for relapsed/refractory indolent non-Hodgkin lymphoma Axicabtagene Ciloleucel (Yescarta; KTE-C19) Non-Hodgkin lymphoma (NHL) Haematological Cancer and Lymphomas 2019 View  |  Download
Axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma – second-line Axicabtagene Ciloleucel (Yescarta; KTE-C19) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Axalimogene Filolisbac for Cervical Cancer – Beyond First Line Treatment Axalimogene filolisbac (ADXS11-001) Cervical cancer Female Reproductive Cancer 2018 View  |  Download
AVXS-101 for spinal muscular atrophy Onasemnogene abeparvovec (Zolgensma; AVXS-101; scAAV9.CB.SMN) Spinal muscular atrophy (SMA) Genetic Disorders , Musculoskeletal System 2018 View  |  Download
Avelumab with or without Pegylated Liposomal Doxorubicin (PLD) for Ovarian Cancer – second line Avelumab (Bavencio; MSB-0010718C) , Pegylated liposomal doxorubicin Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2018 View  |  Download
Avelumab in combination with axitinib for advanced or metastatic renal cell carcinoma – first line Avelumab (Bavencio; MSB-0010718C) , Axitinib (Inlyta; AG-013736) Renal cell carcinoma (RCC) Renal Cancer 2018 View  |  Download
1 2 78 79 80 81 82 87 88
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications